Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001479290-22-000067
Filing Date
2022-05-13
Accepted
2022-05-13 18:11:40
Documents
1
Period of Report
2022-05-04

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_165247985603673.html 4/A  
1 FORM 4/A wf-form4a_165247985603673.xml 4/A 4459
  Complete submission text file 0001479290-22-000067.txt   5875
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560
Business Address
Nolet Chris (Reporting) CIK: 0001782814 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36297 | Film No.: 22924419